Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Welcome and Introduction to Vi3C

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Sep

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Welcome and Introduction to Vi3C

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC

Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC

DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer

MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC

New Executive Director of the Duke Cancer Institute Named